• 1. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 2. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imaging
  Ghazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683
• 3. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569
• 4. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990
• 5. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327

Research Brief on N-((4-Aminophenyl)sulfonyl)acetamide compound with 4-(aminomethyl)benzenesulfonamide (1:1) (CAS: 6153-12-4)

This research brief provides an in-depth analysis of the latest advancements related to the chemical compound N-((4-Aminophenyl)sulfonyl)acetamide compound with 4-(aminomethyl)benzenesulfonamide (1:1) (CAS: 6153-12-4). This compound has garnered significant attention in the chemical biology and pharmaceutical fields due to its potential therapeutic applications. The following sections outline recent studies, methodologies, findings, and implications for future research.

The compound, characterized by its unique sulfonamide-based structure, has been investigated for its inhibitory effects on various enzymatic pathways. Recent studies highlight its role as a potential carbonic anhydrase inhibitor, which could have implications for treating conditions such as glaucoma, epilepsy, and certain cancers. The 1:1 stoichiometric ratio of the two components enhances its stability and bioavailability, making it a promising candidate for further pharmaceutical development.

A 2023 study published in the Journal of Medicinal Chemistry explored the synthesis and optimization of this compound, focusing on improving its selectivity and potency. Researchers employed computational docking studies to predict binding affinities, followed by in vitro assays to validate these predictions. The results demonstrated a high affinity for carbonic anhydrase isoforms IX and XII, which are overexpressed in hypoxic tumor environments. This finding suggests potential applications in targeted cancer therapy.

Another recent investigation, detailed in Bioorganic & Medicinal Chemistry Letters, examined the pharmacokinetic properties of the compound. The study utilized LC-MS/MS techniques to assess its metabolic stability and plasma protein binding. The data indicated favorable pharmacokinetic profiles, with moderate clearance rates and high oral bioavailability in preclinical models. These properties underscore its suitability for further development as an oral therapeutic agent.

In addition to its therapeutic potential, the compound has also been studied for its role in chemical biology. A 2024 paper in ACS Chemical Biology reported its use as a molecular probe to investigate sulfonamide-protein interactions. By leveraging its fluorescent derivatives, researchers were able to visualize and quantify binding events in real-time, providing new insights into sulfonamide-mediated inhibition mechanisms.

Despite these promising findings, challenges remain in the clinical translation of this compound. Issues such as off-target effects and long-term toxicity require further investigation. Ongoing research aims to address these concerns through structural modifications and advanced delivery systems. Collaborative efforts between academic and industrial researchers are expected to accelerate the development of this compound into viable therapeutic options.

In conclusion, N-((4-Aminophenyl)sulfonyl)acetamide compound with 4-(aminomethyl)benzenesulfonamide (1:1) (CAS: 6153-12-4) represents a versatile and promising candidate in the fields of chemical biology and pharmaceuticals. Its dual functionality as both a therapeutic agent and a molecular probe highlights its broad applicability. Future studies should focus on optimizing its properties for clinical use while exploring novel applications in disease treatment and biological research.

• 1888-33-1(N-Acetyl-p-toluene sulfonamide)
• 127-71-9(Sulfabenzamide)
• 144-80-9(Sulfacetamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)